Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Taking away the sting of malaria

Sally Murray
CMAJ January 17, 2006 174 (2) 161-162; DOI: https://doi.org/10.1503/cmaj.051601
Sally Murray
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

More than 40% of the world's population is at risk of malaria, and more than a million people die of it each year. Malaria kills a child every 30 seconds: 90% of people who die from malaria are children not yet 5 years of age, and most (90%) of these deaths take place in sub-Saharan Africa.1

Where malaria is endemic, related illness and death have severe economic as well as human costs. It is estimated that US$12 billion is lost in Africa each year to the costs of care and reduced productivity, and that a high endemic malaria burden lowers the growth of a country's annual GNP (gross national product) by 2%.1

Figure1

Figure. Photo by: CDC

Currently, affected countries are beset by limited access to rapid diagnostic tests and to the resources required to support prevention strategies and overcome drug resistance. Turning the malaria problem around requires an ongoing multipronged attack emphasizing both prevention and treatment.

Malaria is commonly diagnosed and treated according to clinical symptoms rather than laboratory test results; the result of this is that many of the people treated may not in fact be infected. Appropriate diagnosis is limited by a lack of laboratory services, or services of poor quality; and although rapid tests (which are currently effective for Plasmodium falciparum infections only) are available, they are not widely accessible because of their cost.1 The lack of good diagnostic tests increases drug use (and costs), and contributes to more rapid development of drug resistance.2

The treatment of malaria has also become increasingly problematic. Common and sequential use of monotherapies and reliance on quinoline and antifolate compounds have contributed to a burgeoning problem of drug resistance.1,2 In an effort to combat ineffective treatment, the World Health Organization (WHO) has recommended that all countries where resistance to conventional monotherapies such as chloroquine or amodiaquine is common or growing use combination therapies (CTs), preferably ones containing artemisinin derivatives (ACTs). As an indication to switch to ACTs, WHO has also lowered the endemic resistance threshold from 25% to 15% among children younger than 5 years.2

WHO's change in recommendation follows evidence that ACTs are well tolerated, produce rapid therapeutic responses, are effective against P. falciparum and can cure infections after just 3 days of treatment.2 They also reduce gametocyte carriage and may therefore reduce malaria transmission. To improve ease of use, a fixed-dose combination (2 drugs combined in one pill) and dissolvable pills for children are being developed.

Despite clear indications for their use, in 2005 ACTs were used in the public sectors of only 9 countries in Africa. This is partly due to increased cost: ACTs cost 10 times that of older therapies.1 Although the Global Fund for Fighting AIDS, Tuberculosis and Malaria, the largest funder of ACTs in developing countries, has committed US$41 million for ACT purchases, the cost of estimated global requirements (132 million courses, in 2005) far exceeds the funding available.2 The decision to encourage many African countries at once to change to ACTs has also led to global shortages of the drugs, a problem exacerbated by the 6 months of cultivation needed for Artemisia annua plants plus the time required for processing and manufacturing.1

In the meantime, prevention efforts are continuing. Bed nets are being widely promoted, although mass distribution is difficult. In Africa, 30 million nets per year are currently required to meet the target of having 60% of at-risk populations, including young children and pregnant women, protected by nets within 3 years.3 Insecticidal bed nets are being developed that last for 4–5 years without requiring retreatment with insecticide, which would improve prevention efforts.

Intermittent treatment regimens are also recommended for pregnant women to prevent malarial episodes. Pregnant women are particularly vulnerable because of their lowered immunity. Intermittent treatment, involving at least 2 preventive treatments with an effective antimalarial drug during antenatal clinic visits, has been shown to reduce the number of infants with low birth weights.3

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

Box 1.

Finally, clinical trials of malaria vaccines are underway, and new insecticides that are safe for the environment and for people are being developed for larval control.

Current challenges facing malaria control are not new. The battle to control malaria at a global level began with WHO's vector-control programs in the 1950s; as mortality rates rose, WHO introduced the Roll Back Malaria (RBM) program in 1998. Now, other international partners (Box 1) are supporting the development of effective diagnostics, treatment (Box 2) and global management of malaria. It is now up to WHO and its partners to make sure the prevention and treatment objectives outlined in the UN Millennium Development Goals and the 2000 African leaders' summit (Box 3) are met: appropriate and quick treatment, accessible prevention measures and effective epidemic control.

Figure3
  • Download figure
  • Open in new tab
  • Download powerpoint

Box 2.

Figure4
  • Download figure
  • Open in new tab
  • Download powerpoint

Box 3.

REFERENCES

  1. 1.↵
    Greenwood BM, Bojang K, Whitty C, et al. Malaria. Lancet 2005;365:1487-8.
    OpenUrlCrossRefPubMed
  2. 2.↵
    World Health Organization. Roll back malaria: facts on artemisinin-based combination therapies. Geneva: WHO; 2005. Available: www.rbm.who.int/cmc_upload/0/000/015/364/RBMInfosheet_9.htm (accessed 2005 Dec 8).
  3. 3.↵
    Global Fund for Fighting AIDS, Tuberculosis and Malaria (GFATM). HIV/AIDS, tuberculosis and malaria: the status and impact of the three diseases. Geneva: GFATM; 2005.
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 174 (2)
CMAJ
Vol. 174, Issue 2
17 Jan 2006
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Taking away the sting of malaria
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Taking away the sting of malaria
Sally Murray
CMAJ Jan 2006, 174 (2) 161-162; DOI: 10.1503/cmaj.051601

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Taking away the sting of malaria
Sally Murray
CMAJ Jan 2006, 174 (2) 161-162; DOI: 10.1503/cmaj.051601
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • REFERENCES
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights of this issue • Dans ce numéro
  • Highlights of this issue • Dans ce numéro
  • PubMed
  • Google Scholar

Cited By...

  • Syndromic Diagnosis of Malaria in Rural Sierra Leone and Proposed Additions to the National Integrated Management of Childhood Illness Guidelines for Fever
  • Google Scholar

More in this TOC Section

  • Modern Rhesus (Rh) typing in transfusion and pregnancy
  • Remdesivir for patients with COVID-19
  • Syphilis presenting with moth-eaten alopecia
Show more Practice

Similar Articles

Collections

  • Topics
    • Travel medicine

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire